Early-stage liver cancer auxiliary diagnostic biomarker combinations, primer combinations and their applications
By constructing a combination of auxiliary diagnostic biomarkers for early liver cancer and a machine learning model, the problems of insufficient sensitivity and specificity in existing liver cancer diagnostic technologies have been solved, achieving efficient early liver cancer screening that is applicable to the detection of various sample types.
Patent Information
- Application Number
- CN202611620006.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing liver cancer diagnostic technologies lack sensitivity and specificity, making it difficult to accurately identify early-stage liver cancer. Current serum biomarkers also lack diagnostic efficacy, and imaging examinations are insufficient in terms of sensitivity and specificity for early lesions, thus limiting the feasibility of large-scale population screening.
A combination of biomarkers for early-stage liver cancer was constructed, including methylation sites of nine gene biomarkers. By combining a machine learning model and detecting the methylation level of the combination of methylation biomarkers, an early-stage liver cancer auxiliary diagnostic model was established. The model was then used for detection using various methods such as methylation microarray, qPCR, and digital PCR.
It achieves high sensitivity (>90%) and high specificity (>90%) in early liver cancer screening, has good prospects for clinical translational application, and is suitable for large-scale population screening.
Smart Images

Figure CN123108153A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of liver cancer diagnostic technology, and more specifically, to combinations of auxiliary diagnostic biomarkers and primer combinations for early liver cancer and their applications. Background Technology
[0002] Liver cancer, a malignant tumor with high incidence and mortality rates worldwide, continues to pose a severe disease burden. Data from the International Agency for Research on Cancer (IARC) predicts that by 2040, the number of new liver cancer cases and deaths globally will increase by more than 55% compared to current levels. It is noteworthy that although epidemiological studies confirm that approximately 70%-90% of liver cancer cases can be prevented through risk factor interventions, it still ranks as the third leading cause of cancer-related deaths globally. Clinical data shows that the five-year overall survival rate for early-stage liver cancer patients receiving radical treatment can reach 69%-86%; however, approximately 70% of liver cancer patients are diagnosed at an advanced stage, losing the opportunity for radical treatment, causing the five-year survival rate to plummet to 5%-30%. This situation highlights the significant importance of accurate identification in the early stages of liver cancer for improving patient clinical outcomes.
[0003] Current clinical diagnostic systems for liver cancer primarily rely on the combined use of serological markers (including alpha-fetoprotein, abnormal prothrombin, phosphatidylinositol proteoglycan-3, and Golgi protein 73) and imaging examinations. However, this diagnostic model has significant limitations: First, the diagnostic efficacy of existing serological markers is insufficient. For example, in primary hepatocellular carcinoma, only about 60% of patients show abnormal alpha-fetoprotein levels, indicating a significant risk of false negatives. Second, while ultrasound examination has an overall sensitivity of 84% for liver cancer, its sensitivity and specificity for early lesions are only 63% and 45%, respectively, which is insufficient to meet the accuracy requirements for early screening. This dual technical bottleneck makes the current approach highly dependent on operator experience and equipment performance, severely restricting the feasibility of large-scale population screening.
[0004] Breakthrough advances in epigenetics research have provided new insights into the early detection of liver cancer. Extensive evidence suggests that abnormal DNA methylation, as an early molecular event in tumorigenesis, exhibits superior temporal sensitivity and tissue specificity compared to traditional protein biomarkers. In particular, methylation detection technologies based on circulating cell-free DNA (cfDNA) demonstrate significant clinical translational potential due to their non-invasive sampling advantages. However, existing technologies still face multiple challenges: first-generation methylation detection technologies (such as qPCR) are limited by the number of target sites, making multi-gene synergistic analysis difficult; while whole-genome methylation sequencing, although capable of providing a panoramic view of methylation profiles, faces technical barriers such as high detection costs and extremely low ctDNA abundance (typically <0.1%). More importantly, the methylation levels at different sites within the same CpG island can vary by orders of magnitude, and this site heterogeneity significantly increases the complexity of data analysis.
[0005] Based on the aforementioned technical challenges, the core research focus is on constructing a methylation detection system that is highly sensitive (>85%), highly specific (>90%), and cost-effective. This involves optimizing target site selection strategies, developing highly sensitive detection methods, and establishing intelligent data analysis models to ultimately achieve a breakthrough in the clinical translation of early liver cancer screening technology. Achieving this goal will directly drive a paradigm shift in liver cancer prevention and control strategies from "passive diagnosis and treatment" to "proactive prevention and control."
[0006] In view of this, the present invention is proposed. Summary of the Invention
[0007] The purpose of this invention is to provide a combination of biomarkers and primers for the auxiliary diagnosis of early liver cancer and their applications.
[0008] This invention is implemented as follows: In a first aspect, the present invention provides the application of a reagent for detecting a combination of methylation biomarkers in the preparation of auxiliary diagnostic or diagnostic products for early liver cancer. The reagent is used to detect the methylation level of the combination of methylation biomarkers, which includes biomarkers 1-9. The positional information of biomarkers 1-9 based on the GRch37 reference genome is as follows: Marker 1: chr12:131303649-131303805; Marker 2: chr5:37834882-37835039; Marker 3: chr5:42994735-42994854; Marker 4: chr2:264102-264234; Marker 5: chr17:29298077-29298218; Marker 6: chr3:179168821-179168951; Marker 7: chr6:26240698-26240819; Marker 8: chr1:226411760-226411845; Marker 9: chr7:27214013-27214164.
[0009] Secondly, the present invention also provides a primer combination for the auxiliary diagnosis or diagnosis of early liver cancer, comprising: a first primer pair, a second primer pair, a third primer pair, a fourth primer pair, a fifth primer pair, a sixth primer pair, a seventh primer pair, an eighth primer pair, and a ninth primer pair, respectively used to detect markers 1 to 9 mentioned above, wherein the nucleotide sequences of the first primer pair to the ninth primer pair are shown in SEQ ID NO.1-SEQ ID NO.18, respectively.
[0010] Thirdly, the present invention also provides a reagent kit, gene chip, or detection device comprising the primer combination described above for the auxiliary diagnosis or diagnosis of early liver cancer.
[0011] Fourthly, the present invention also provides a method for constructing an early liver cancer auxiliary diagnosis or diagnostic model. The early liver cancer auxiliary diagnosis or diagnostic model is constructed by the following method: obtaining the methylation rate of the region where each marker in the combination of methylation markers in the training sample is located, and establishing a dataset; using the dataset and a machine learning model, constructing an early liver cancer auxiliary diagnosis or diagnostic model. The machine learning model is selected from at least one of the following: logistic regression, random forest, K-nearest neighbors, support vector machine, gradient boosting machine, AdaBoost, XGBoost, Naive Bayes, and DT decision tree; When the machine learning model is logistic regression, the model prediction value of the early liver cancer auxiliary diagnosis or diagnostic model is calculated based on the average methylation rate of all methylation sites in the region of each marker in the combination of methylation markers in the tested sample. Model predicted value = Σ (average methylation rate_i × weight coefficient_i), where i represents the marker number, and its value ranges from 1 to 9; the model predicted value is compared with the preset threshold. If the model predicted value is greater than the preset threshold, it is judged as early-stage liver cancer positive. The sample to be tested is selected from cells, tissues, plasma, urine or whole blood.
[0012] Fifthly, the present invention also provides a computer-readable storage medium storing an executable program instruction set, which is loaded by a processor and executed to construct the aforementioned early liver cancer diagnostic model and to diagnose early liver cancer.
[0013] The present invention has the following beneficial effects: Through multiple rounds of screening and validation, this invention identified 109 methylation sites of 9 gene markers from initial candidate gene markers and conducted systematic validation in leukocyte and plasma samples. This invention also constructed a liver cancer diagnostic model, which showed more than 90% specificity and high detection sensitivity for early liver cancer diagnosis, which is helpful for "early screening, early diagnosis and early treatment" and has good prospects for clinical translational application. Attached Figure Description
[0014] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.
[0015] Figure 1 The ROC curve of the diagnostic results of Model 1 of this invention on the training set; Figure 2 This is the ROC curve of the diagnostic results of Model 2 of this invention on the training set; Figure 3 The ROC curve of the diagnostic results of Model 3 of this invention on the training set; Figure 4 The ROC curve of the diagnostic results of Model 1 of this invention on the validation set; Figure 5 The ROC curve of the diagnostic results of Model 2 of this invention on the validation set; Figure 6 This is the ROC curve of the diagnostic results of Model 3 of this invention on the validation set. Detailed Implementation
[0016] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.
[0017] The term "subject" as used in this article can be understood as anyone involved in early liver cancer screening or liver cancer screening.
[0018] The term "threshold" refers to a threshold used in diagnosing the risk of early-stage liver cancer. It compares the methylation rate of a combination of biomarkers in a subject's sample to a specific threshold, and outputs the subject's risk or prognosis based on the comparison result. Specifically, the threshold includes, but is not limited to, a positive cutoff value—a critical value used to delineate results and define the boundaries of judgment. The threshold must be set based on the performance requirements of the target detection scenario (such as sensitivity, specificity, and accuracy), and determined through clinical data validation, statistical model analysis (such as ROC curve analysis and Youden's index calculation), or industry standard calibration to ensure its validity and reliability in the detection method or diagnostic model.
[0019] Methylation rate at each site = number of methylated reads / (number of methylated reads + number of unmethylated reads).
[0020] The average methylation rate of each marker region is calculated based on its site.
[0021] The term "early-stage liver cancer" includes stage 0 (very early stage), stage I, and stage II.
[0022] In a first aspect, the present invention provides the application of a reagent for detecting a combination of methylation biomarkers in the preparation of auxiliary diagnostic or diagnostic products for early liver cancer. The reagent is used to detect the methylation level of the combination of methylation biomarkers, which includes biomarkers 1-9. The positional information of biomarkers 1-9 based on the GRch37 reference genome is as follows: Marker 1: chr12:131303649-131303805; Marker 2: chr5:37834882-37835039; Marker 3: chr5:42994735-42994854; Marker 4: chr2:264102-264234; Marker 5: chr17:29298077-29298218; Marker 6: chr3:179168821-179168951; Marker 7: chr6:26240698-26240819; Marker 8: chr1:226411760-226411845; Marker 9: chr7:27214013-27214164.
[0023] Furthermore, marker 1 includes the following methylation sites: chr12:131303667, chr12:131303677, chr12:131303690, chr12:131303700, chr12:131303704, chr12:131303707, chr12:131303724, chr12:131303740, chr12:131303751, chr12:131303767, chr12:131303774, chr12:131303786; Marker 2 includes the following methylation sites: chr5:37835032, chr5:37835022, chr5:37835016, chr5:37835000, chr5:37834990, chr5:37834970, chr5:37834959, chr5:37834939, chr5:37834931, chr5:37834929, chr5:37834920, chr5:37834917, chr5:37834914, and chr5:37834910.
[0024] Marker 3 includes the following methylation sites: chr5:42994755, chr5:42994764, chr5:42994771, chr5:42994776, chr5:42994783, chr5:42994787, chr5:42994789, chr5:42994812, chr5:42994823, chr5:42994835; Marker 4 includes the following methylation sites: chr2:264120, chr2:264123, chr2:264129, chr2:264134, chr2:264136, chr2:264150, chr2:264152, chr2:264156, chr2:264159, chr2:264164, chr2:264166, chr2:264178, chr2:264193, chr2:264199, chr2:264204, chr2:264216; Marker 5 includes the following methylation sites: chr17:29298096, chr17:29298115, chr17:29298118, chr17:29298124, chr17:29298136, chr17:29298142, chr17:29298148, chr17:29298184, chr17:29298189, and chr17:29298199; Marker 6 includes the following methylation sites: chr3:179168840, chr3:179168843, chr3:179168847, chr3:179168854, chr3:179168861, chr3:179168866, chr3:179168870, chr3:179168880, chr3:179168884, chr3:179168897, chr3:179168900, chr3:179168903, chr3:179168907, chr3:179168922, chr3:179168924; Marker 7 includes the following methylation sites: chr6:26240797, chr6:26240790, chr6:26240783, chr6:26240780, chr6:26240777, chr6:26240775, chr6:26240772, chr6:26240763, chr6:26240760, chr6:26240753, chr6:26240746, chr6:26240724; Marker 8 includes the following methylation sites: chr1:226411824, chr1:226411819, chr1:226411813, chr1:226411805, chr1:226411803, chr1:226411795, chr1:226411791, chr1:226411786; Marker 9 includes the following methylation sites: chr7:27214035, chr7:27214041, chr7:27214043, chr7:27214049, chr7:27214056, chr7:27214062, chr7:27214075, chr7:27214077, chr7:27214119, chr7:27214126, chr7:27214139, and chr7:27214146.
[0025] The methylation levels of the DNA regions of the above nine biomarkers differ between early-stage liver cancer patients and healthy individuals.
[0026] In a preferred embodiment of the present invention, the auxiliary diagnostic or diagnostic products for early liver cancer are selected from reagent kits, gene chips, and detectors.
[0027] In a preferred embodiment of the present invention, the reagent for detecting the combination of methylation markers is selected from at least one reagent used in a method for detecting the methylation level of the combination of methylation markers: Methylation chip method, qPCR method, digital PCR method, second-generation sequencing method, third-generation sequencing method, HPLC method and MassArray.
[0028] In a preferred embodiment of the present invention, the reagents used to detect the combination of methylation markers are those used in bisulfite conversion sequencing or pyrosequencing.
[0029] In one embodiment, the bisulfite conversion sequencing method is selected from whole-genome methylation sequencing or simplified bisulfite sequencing technology.
[0030] The reagents for detecting combinations of methylation markers can also be the same reagents used in methylation-specific PCR.
[0031] In a preferred embodiment of the present invention, the reagent for detecting the methylation marker combination is a primer combination for detecting the methylation marker combination. The primer combination includes: a first primer pair, a second primer pair, a third primer pair, a fourth primer pair, a fifth primer pair, a sixth primer pair, a seventh primer pair, an eighth primer pair, and a ninth primer pair, respectively, for detecting markers 1 to 9. The nucleotide sequences of the first primer pair to the ninth primer pair are shown in SEQ ID NO.1-SEQ ID NO.18, respectively.
[0032] The nucleotide sequences of the primer combinations are shown in Table 1 below: Table 1 Primer sequence listing
[0033] In Table 1, Y represents C / T and R represents A / G.
[0034] Secondly, the present invention also provides a primer combination for the auxiliary diagnosis or diagnosis of early liver cancer, comprising: a first primer pair, a second primer pair, a third primer pair, a fourth primer pair, a fifth primer pair, a sixth primer pair, a seventh primer pair, an eighth primer pair, and a ninth primer pair, respectively used to detect markers 1 to 9 mentioned above, wherein the nucleotide sequences of the first primer pair to the ninth primer pair are shown in SEQ ID NO.1-SEQ ID NO.18, respectively.
[0035] Thirdly, the present invention also provides a reagent kit, gene chip, or detection device comprising the primer combination described above for the auxiliary diagnosis or diagnosis of early liver cancer.
[0036] In one embodiment, the above-mentioned kit, gene chip, or detection device includes: sulfite conversion reagent, PCR amplification reagent (including enzymes, dNTPs, and buffer), magnetic bead purification reagent, and NGS library construction reagent.
[0037] In a preferred embodiment of the present invention, the kit, gene chip, or detection device further includes detection primers for detecting the methylation level of the internal reference gene (ACTB); Its primer sequences are shown in SEQ ID NO.19-SEQ ID NO.20.
[0038] The methylation sites of the internal reference gene include: chr7:5571938, chr7:5571933, chr7:5571932, chr7:5571926, chr7:5571921, chr7:5571917, chr7:5571916, chr7:5571915, chr7:5571912, chr7:5571911, chr7:5571910, chr7:5571909, chr7:5571902, chr7:5571891, chr7:5571887, and chr7:5571874. chr7:5571873、chr7:5571872、chr7:5571868、chr7:5571846、chr7:5571844、chr7:5571841、chr7:5571836、chr7:5571833、chr7:5 571828, chr7:5571821, chr7:5571820, chr7:5571814, chr7:5571811, chr7:5571810, chr7:5571808, chr7:5571801, chr7:5571789.
[0039] In all samples, the methylation conversion rate of multiple methylation sites on the internal reference gene marker ACTB was greater than 99.5%, indicating successful methylation conversion in this detection step. Conversion rate = 1 - (number of unconverted cytosines / total number of cytosines at the detection site) × 100%. A conversion rate of ACTB in the internal reference region > 99.5% is required; otherwise, the tested sample will be discarded.
[0040] Quality control is ensured by an internal control ACTB conversion rate of >99.5%, providing a panoramic high-resolution view that is superior to the qualitative detection of first-generation Q-PCR.
[0041] Fourthly, the present invention also provides a method for constructing an early liver cancer auxiliary diagnosis or diagnostic model. The early liver cancer auxiliary diagnosis or diagnostic model is constructed by the following method: obtaining the methylation rate of the region where each marker in the combination of methylation markers in the training sample is located, and establishing a dataset; using the dataset and a machine learning model, constructing an early liver cancer auxiliary diagnosis or diagnostic model. The machine learning model is selected from at least one of the following: logistic regression, random forest, K-nearest neighbors, support vector machine, gradient boosting machine, AdaBoost, XGBoost, Naive Bayes, and DT decision tree; When the machine learning model is logistic regression, the model prediction value of the early liver cancer auxiliary diagnosis or diagnostic model is calculated based on the average methylation rate of all methylation sites in the region of each marker in the combination of methylation markers in the tested sample. Model predicted value = Σ (average methylation rate_i × weight coefficient_i), where i represents the marker number, and its value ranges from 1 to 9; the model predicted value is compared with the preset threshold. If the model predicted value is greater than the preset threshold, it is judged as early-stage liver cancer positive; if the model predicted value is less than or equal to the preset threshold, it is judged as early-stage liver cancer negative.
[0042] In one implementation, the LogisticRegression model (solver='liblinear') from the Python sklearn library is used.
[0043] The method for calculating the weight coefficients (w) in logistic regression is as follows: Let the features be $x = (x_1, x_2, ..., x_n)$, the coefficients be $\boldsymbol{w} = (w_1, w_2, ..., w_n)$, and the bias be $w_0$.
[0044] (1) Linear part: $$z = w_0 + w_1x_1 + w_2x_2 + \dots + w_nx_n = \boldsymbol{w}^T\boldsymbol{x}$$; (2) Solve for the pre-weight coefficients of the above features: Core logic: The Sigmoid function maps linear predicted values to the [0,1] interval, representing the probability that the dependent variable is 1. (i) Sigmoid function: $$\sigma(z) = \frac{1}{1+e^{-z}}$$, with a range of $(0,1)$, is used to map linear combinations to probabilities.
[0045] (ii) Predicted probabilities after mapping: $$\hat y = \sigma(\boldsymbol{w}^T\boldsymbol{x}) = \frac{1}{1+e^{-\boldsymbol{w}^T\boldsymbol{x}}}$$.
[0046] (iii) Binary label $y\in\{0,1\}$.
[0047] The solution for w in the predicted probability is not unique. To find the solution for w in this formula, we use... Iterative Weighted Least Squares (IRLS) It can be written in the following form: $$\boldsymbol{w}_{k+1} = \boldsymbol{w}_k - (X^TWX)^{-1}X^T(\hat y- y)$$; $W$ is a diagonal weight matrix composed of predicted probabilities.
[0048] (iv) Input the binary classification label y of the training set and the methylation rate x of the training set data into the formula, and iterate continuously according to the gradient convergence to finally obtain the weight coefficients.
[0049] In a preferred embodiment of the present invention, the sample to be tested is selected from cells, tissues, plasma, urine, or whole blood. The biomarker combination provided by the present invention has good diagnostic efficacy for a variety of samples and has the technical advantage of wide applicability.
[0050] Fifthly, the present invention also provides a method for the auxiliary diagnosis or diagnosis of early liver cancer, wherein all steps of the method are implemented by a computer, and the method includes: inputting the methylation rate of the region where each marker in the combination of methylation markers in the subject's sample is located, wherein the combination of methylation markers is the combination of methylation markers mentioned above; and obtaining the auxiliary diagnosis or diagnosis result of early liver cancer of the tested sample based on the auxiliary diagnosis or diagnosis model of early liver cancer.
[0051] The diagnostic method provided by this invention enables non-invasive and rapid detection, especially based on cell-free DNA in plasma. Its sample collection is simple, and the entire process includes lysis, sulfite conversion, library construction and sequencing, achieving non-invasive early signal detection, which is suitable for large-scale screening.
[0052] In a sixth aspect, the present invention also provides a computer-readable storage medium storing an executable program instruction set, which is loaded by a processor and executed to construct the aforementioned early liver cancer diagnostic model and to diagnose early liver cancer.
[0053] The term "computer-readable storage medium" includes data storage media or cloud drives based on a single physical entity such as a CD, CD-ROM, hard disk, optical storage medium, or magnetic disk. Furthermore, the term also includes data storage media composed of physically separate entities that are effectively connected to each other, preferably in a query-and-search manner, to provide the aforementioned data set.
[0054] In a seventh aspect, the present invention also provides an apparatus for early diagnosis of liver cancer, the apparatus including a processor and a memory, the memory storing a set of executable program instructions, the set of executable program instructions being loaded and executed by the processor to realize the above-mentioned auxiliary diagnosis or diagnosis method for early liver cancer.
[0055] Specifically, the electronic device may include a memory, a processor, a bus, and a communication interface, which are electrically connected directly or indirectly to each other to enable data transmission or interaction. For example, these components may be electrically connected to each other via one or more buses or signal lines. The processor may process information and / or data related to target identification to perform one or more functions described in this application.
[0056] The memory can be, but is not limited to, Random Access Memory (RAM), Read Only Memory (ROM), Programmable Read-Only Memory (PROM), Erasable Programmable Read-Only Memory (EPROM), Electrically Erasable Programmable Read-Only Memory (EEPROM), etc.
[0057] A processor can be an integrated circuit chip with signal processing capabilities. This processor can be a general-purpose processor, including a Central Processing Unit (CPU), a Network Processor (NP), etc.; it can also be a Digital Signal Processor (DSP), an Application Specific Integrated Circuit (ASIC), a Field-Programmable Gate Array (FPGA), or other programmable logic devices, discrete gate or transistor logic devices, or discrete hardware components.
[0058] The features and performance of the present invention will be further described in detail below with reference to embodiments.
[0059] Example 1 This embodiment provides an experimental method for detecting the methylation level of candidate biomarkers in a sample to be tested.
[0060] The experimental method is as follows: (a) Collection of blood samples 1. Whole blood collection Blood collection method: Disposable vacuum blood collection tubes (Zhejiang Medical Device Registration Certificate No. 20232221417) were used to collect 10 ml of blood in the morning on an empty stomach from 148 patients with early stage (stage I and II) liver cancer (mean age 56 years, females accounted for 61.49%, of which 105 were included in the training set and 43 in the validation set) and 91 healthy individuals (mean age 58.5 years, females accounted for 62.63%, of which 54 were included in the training set and 37 in the validation set).
[0061] 2. Preparation of plasma samples Centrifuge the blood collection tube containing whole blood for 12 minutes at a centrifugal force of 1500 rcf. Remove the blood collection tube from the centrifuge and transfer the supernatant plasma into a labeled 2 mL centrifuge tube to obtain the sample required for the experiment.
[0062] (ii) Pretreatment of cell-free DNA in plasma The methylation detection sample pretreatment reagent (plasma sample extraction and bisulfite conversion kit (magnetic bead method), manufacturer: Jiaxing Yunying Medical Laboratory Co., Ltd.; catalog number: C128) was used to lyse, convert, and purify the sample. The operation steps are as follows.
[0063] 1. Preparation of reagents in the kit: Prepare the reagents in the above kit according to Table 2 below.
[0064] Table 2. Reagent Preparation
[0065] 2. Plasma DNA extraction: Take 1.8 ml of plasma, add 100 μL of 20% SDS, mix by inverting, centrifuge briefly, then add 30 μL of PK enzyme (20 mg / mL), vortex 4-5 times to mix; incubate at 60℃ for 40 min, then at 80℃ for 20 min, place at room temperature for 5 min, and centrifuge briefly.
[0066] The above mixture was further extracted using an Auto-Pure-20B purifier. The program was run according to the settings. After the program was completed, the liquid was taken out from the last well and placed into a new PCR tube. The tube was labeled with the corresponding sample number. This is the plasma cell-free DNA sample, which can be used for the next step of sulfite conversion.
[0067] (1) Sample addition: Add all the solution in the EP tube to column 1 of the purification kit (add different samples to different wells) and record the sample number; (2) After installing the magnetic rod sleeve, place the purification kit into the fully automated nucleic acid extractor and set it up and operate it according to the prescribed procedure: (3) After the program runs, the solution is aspirated into a new 0.5 mL centrifuge tube. The collected solution is the plasma DNA sample, which is quantified using a Qubit fluorometer.
[0068] (III) Sulfite Conversion 1. System preparation: Prepare sulfite reaction systems in 0.5 mL PCR tubes according to the table below for the extracted DNA samples.
[0069] Table 3. Conversion Table for Sulfite Reaction System
[0070] 2. Sulfite Conversion After vortexing and mixing, and briefly centrifuging, place the PCR tube in a PCR instrument and incubate at 95℃ for 5 min and 85℃ for 60 min. After incubation, cool to room temperature and briefly centrifuge to obtain the transformation product.
[0071] (iv) Bis-DNA purification treatment The purified product was run using the Auto-Pure-32A purifier according to the set program. After the run was completed, the liquid was removed from the well and placed into a new PCR eight-tube strip, which was then labeled with the corresponding sample number. This is the purified Bis-DNA, which can be used for the next library enrichment reaction.
[0072] (v) Library enrichment reaction The Bis DNA obtained after purification in the previous step was subjected to a library enrichment reaction.
[0073] Preparation of enrichment PCR reaction.
[0074] Prepare the enrichment reaction solution as needed according to the formula shown in Table 4. After preparation, aliquot the solution into clean eight-slot containers. The aliquoted enrichment reaction solutions are grouped according to the mixed primers and named MZ Enrichment PCR Reaction Strip-1 to MZ Enrichment PCR Reaction Strip-4. Divide the nine cancer biomarker primers and one internal control biomarker primer from Table 1 into four combinations, each containing different biomarker primers. Use the four mixed enrichment reaction solutions for enriching different biomarkers, and name them MZ Enrichment PCR Reaction Strip-1 to MZ Enrichment PCR Reaction Strip-4 respectively.
[0075] Table 4. Enrichment Reaction Table
[0076] The enrichment reaction shall be carried out according to the following steps: 1. Gently open the caps of tubes MZ enriched PCR reaction strip-1 to MZ enriched PCR reaction strip-4 prepared in the previous step, and add 1 μL of Taq enzyme to MZ enriched reaction solution-1 to MZ enriched PCR reaction solution-4 respectively, ensuring that the pipette tip is fully inserted into the reaction solution; 2. Add 20 μL of the Bis DNA sample to be tested after sulfite conversion to the four enrichment reaction strips in sequence along the PCR tube wall, and carefully close the tube caps. 3. After vortexing the PCR reaction strip to mix well, centrifuge, taking care to avoid air bubbles; 4. Place the above four enrichment PCR reaction strips into the PCR instrument; 5. Open the PCR instrument settings interface, set the amplification program according to Table 5 below, and perform PCR amplification.
[0077] Table 5. PCR reaction procedure for library enrichment
[0078] (vi) Library preparation reaction Preparation for the connector connection reaction: Prepare the required number of adapters according to the formula shown in Table 6 (excluding Ace Taq enzyme and the PCR reaction product enriched in the previous step). Alternatively, prepare the adapters in advance and aliquot them into clean eight-tube tubes. Store at -20°C for later use.
[0079] After removing the connector reaction solution from the refrigerator and allowing it to melt, centrifuge it briefly in a centrifuge before use.
[0080] Table 6. Reaction Components for Library Preparation
[0081] Library preparation specifically includes the following steps: 1. Gently open the cap of the reaction strip connector and add 0.5 μL of Taq enzyme into the reaction strip connector, ensuring that the pipette tip is fully inserted into the reaction solution; 2. Take 5 μL of the enriched PCR amplification product from the previous step and add it sequentially along the wall of the PCR tube to the adapter connection reaction strip, then carefully close the tube cap. 3. Connect the connector to the reaction strip, shake to mix thoroughly, and then centrifuge, taking care to avoid air bubbles; 4. Connect the above-mentioned adapter to the reaction strip and place it into the PCR instrument; 5. Open the PCR instrument settings interface, set the amplification program according to Table 7 below, and perform PCR amplification.
[0082] Table 7. PCR Reaction Procedure for Library Preparation
[0083] (vii) Sorting of Library Products 1. Remove the magnetic beads used for purification, shake to mix, and incubate at room temperature for at least 30 minutes; 2. Take 20 μL, 20 μL, 15 μL and 15 μL of MZ library-1, MZ library-2, MZ library-3 and MZ library-4 respectively and add them to a new eight-tube, so that the total volume of the libraries in the reaction tube is 70 μL. 3. Take 126 μL of the incubated magnetic beads (shake well again before use) and add them sequentially to each sample reaction tube. Shake well and then incubate briefly to completely mix and resuspend the DNA and magnetic beads. 4. Incubate at room temperature for 5 minutes; 5. Incubate on a magnetic rack for 5 minutes until the solution is clear. Carefully aspirate and discard the supernatant, being careful not to disturb the magnetic beads. 6. Add 200µL of freshly prepared 80% ethanol solution (the ethanol solution should just cover the magnetic bead sample), place it on a magnetic rack, and incubate it on the magnetic rack for 30 seconds until the solution is clear. Discard the supernatant. 7. Repeat step 6 above for a second wash; 8. Ensure that the ethanol solution in the centrifuge tube has been completely discarded, and place the eight-tube or PCR tube on a magnetic rack to air dry at room temperature for 3-5 minutes; 9. Remove the eight-tube or PCR tube from the magnetic rack, add 70 μL of purified water to fully wet the magnetic beads, shake well to mix, and then quickly centrifuge to collect the liquid at the bottom of the tube. Let it stand at room temperature for 5 min. 10. Place the 8-tube or PCR tube on a magnetic rack and let it stand for 5 minutes until the solution is clear. Transfer 60 μL of the supernatant to a new 8-tube or 1.5 mL centrifuge tube to obtain the sequencing library. Use the Equalbit 1×dsDNA HS Assay Kit and its matching Qubit fluorescence instrument to detect the concentration. The library concentration should be ≥1 ng / μL. Otherwise, the library preparation sample does not meet the requirements and should be reconstructed.
[0084] 11. Perform deep sequencing on an Illumina MiniSeq sequencer, with each sample being sequenced at 200M.
[0085] (viii) Methylation data processing workflow: The first step is data processing and quality control.
[0086] 1. The methylation rate of 109 methylation sites of 9 gene markers in plasma samples from liver cancer positive and normal individuals was statistically analyzed. The methylation rate of a site was calculated as the number of methylated reads at that site / (number of methylated reads at that site + number of unmethylated reads at that site). After removing methylation site data located on primers and excluding methylation rates of methylation sites with sequencing depths below 10000X, the average methylation rate of all methylation sites within each marker was calculated to represent the methylation rate of that gene marker.
[0087] Among them, marker 1 includes 12 methylation sites, marker 2 includes 14 methylation sites, marker 3 includes 10 methylation sites, marker 4 includes 16 methylation sites, marker 5 includes 10 methylation sites, marker 6 includes 15 methylation sites, marker 7 includes 12 methylation sites, marker 8 includes 8 methylation sites, and marker 9 includes 12 methylation sites.
[0088] 2. The methylation conversion rate of all 33 methylation sites on the internal reference gene marker ACTB in all samples was greater than 99.5%, indicating that the methylation conversion in this experiment was successful.
[0089] The second step is model training. The methylation rates of the nine gene markers selected from the training set data are substituted into the logistic regression model for training. The coefficients and thresholds corresponding to each gene marker are obtained. The methylation level of each gene marker is multiplied by the corresponding coefficient and then added together. If the sum is greater than the threshold, the sample is judged as positive; otherwise, it is negative.
[0090] The third step is model tuning and evaluation. The weights of the dependent variable in the model are adjusted according to the ratio of positive and negative data to balance the training set data. The regularization parameters are tuned to find the optimal parameters. The threshold is adjusted to adapt to clinical testing. The sensitivity and specificity of different models are calculated. ROC curves are plotted to evaluate the excellence of different models and select the best model.
[0091] The fourth step is to perform model validation analysis on the validation set using the optimal model described above, calculate its sensitivity and specificity, and plot the ROC curve.
[0092] Based on the above experimental methods, and through multiple rounds of screening and validation, a method for detecting methylation biomarkers in early liver cancer based on NGS sequencing technology was established. 109 methylation sites of 19 gene biomarkers were selected from the initial candidate biomarkers and systematically validated in leukocyte and plasma samples. Finally, a logistic regression detection model was constructed.
[0093] Example 2 This embodiment provides a screening process for combinations of methylation biomarkers. From an initial pool of 14 candidate biomarkers, 109 methylation sites in 9 DNA regions were selected and systematically validated in leukocyte and plasma samples. Finally, a logistic regression detection model was constructed. Screening was based on metrics such as methylation rate, sequencing depth, contribution rate, and specificity.
[0094] (I) Preliminary screening experiment for white blood cells in normal individuals Fourteen candidate gene biomarkers were initially tested using normal human leukocyte samples. The information of each gene biomarker is shown in Table 1. The methylation rate and sequencing depth of each gene biomarker were confirmed, and gene biomarkers with an average methylation rate of less than 10% at methylation sites were screened to provide a basis for subsequent validation.
[0095] Experimental methods: 1. Collect white blood cell samples from 20 normal individuals; 2. Perform PCR amplification using candidate primer combinations; 3. Perform NGS sequencing to analyze the average methylation rate and average sequencing depth of methylation sites; 4. Screening criteria: average methylation rate <10%, average sequencing depth >100×.
[0096] Experimental Results and Analysis: 1. All biomarkers showed good sequencing depth, meeting the requirement of sequencing depth >100×; 2. Among the 14 biomarkers, based on the average methylation rate and average sequencing depth of each biomarker, two biomarkers (chr8:105319004-105319158, chr7:29606038-29606117) had an average methylation rate >10%, which did not meet the screening criteria. 3. The 12 selected gene markers have entered the validation stage of liver cancer plasma testing.
[0097] The primer sequences and methylation site information for candidate biomarkers 10-14 are shown in Table 8 below: Table 8 Primer sequence information for candidate biomarkers 10-14
[0098] Conclusion: Twelve candidate biomarkers with low methylation rates and good sequencing depth in normal human leukocytes were successfully screened, laying the foundation for subsequent validation in plasma samples.
[0099] (II) Plasma sensitivity testing in liver cancer patients Experimental Objective: To validate the biomarkers screened in Experiment 1 in plasma samples from patients with liver cancer, to evaluate the contribution rate of each biomarker in the plasma of patients with liver cancer, and to screen biomarker combinations suitable for detection in the plasma of patients with liver cancer.
[0100] Experimental methods: 1. Collect plasma samples from 20 patients with liver cancer; 2. The primer combinations screened in Experiment 1 were used for detection; 3. Analyze the contribution rate of each biomarker in the plasma of patients with liver cancer; Experimental Results and Analysis: The 12 biomarkers screened in Experiment (I) were used as positive markers with an average methylation rate greater than 10% and a contribution rate greater than 30%. Statistical calculations were performed, and two biomarkers (chr1:116381788-116381878 and chr2:222436219-222436316) had a contribution rate of less than 30%, which did not meet the screening criteria (Table 9).
[0101] Conclusion: Ten biomarkers with good contribution rates in the plasma of patients with liver cancer were successfully screened.
[0102] Table 9 Contribution rate of plasma biomarkers
[0103] (III) Plasma-specific detection Experimental objective: To validate biomarkers with high contribution rates in hepatocellular carcinoma plasma in normal human plasma samples, to evaluate the specificity of each biomarker in normal human plasma, and to screen out biomarkers with high specificity.
[0104] Experimental methods: 1. Collect plasma samples from 20 healthy individuals; 2. Detection was performed using primer combinations for screening liver cancer plasma; 3. Analyze the specificity of each biomarker in normal human plasma; Experimental Results and Analysis: Ten biomarkers were screened from hepatocellular carcinoma plasma. A positive marker was defined as an average methylation level greater than 10% for each biomarker, and a specificity of ≥95% was required for screening. One biomarker (chr2:63281223-63281319) had a specificity lower than 95% and did not meet the screening criteria. Nine biomarkers with high specificity were selected to provide reliable data for model construction, as shown in Table 10.
[0105] Table 10. Specificity results of the 10 candidate biomarkers
[0106] In summary, through multiple rounds of screening, nine biomarker combinations were finally identified, totaling 109 methylation sites, for model construction.
[0107] Example 3 This embodiment involves sample collection, data processing, and the construction of a liver cancer detection model.
[0108] 1. Sample Collection Whole blood collection We used disposable vacuum blood collection tubes (Zhejiang Medical Device Registration Certificate No. 20232221417) to collect and preserve 10 ml of blood in the morning fasting state from 148 patients with early-stage (stage I and II) liver cancer (mean age 56 years, females accounting for 61.49%, of which 105 were included in the training set and 43 in the validation set) and 91 healthy individuals (mean age 58.5 years, females accounting for 62.63%, of which 54 were included in the training set and 37 in the validation set).
[0109] 2. DNA extraction and sulfite conversion Cell-free DNA was extracted from plasma samples and transformed using a sulfite transformation kit. Transformation efficiency was assessed using the transformation rate of the internal control region ACTB, calculated as: Transformation rate = (Number of transformed cytosines / Total number of cytosines at the detection site) × 100%. A transformation rate > 99.5% was required; otherwise, the sample was discarded.
[0110] 3. Targeted amplification and NGS sequencing Targeted amplification was performed using the primer combinations described above. After purification, the amplified products were deep sequenced on an Illumina MiniSeq sequencer (150M reads per sample). Sequencing data processing included removing primer sites and filtering sites with sequencing depths lower than 10000X. The methylation rate for each site was calculated as: number of methylated reads / (number of methylated reads + number of unmethylated reads).
[0111] The average methylation rate of each marker region is calculated based on its methylation sites: Among them, marker 1 includes 12 methylation sites, marker 2 includes 14 methylation sites, marker 3 includes 10 methylation sites, marker 4 includes 16 methylation sites, marker 5 includes 10 methylation sites, marker 6 includes 15 methylation sites, marker 7 includes 12 methylation sites, marker 8 includes 8 methylation sites, and marker 9 includes 12 methylation sites.
[0112] 4. Model Training and Optimization Three models were trained using the LogisticRegression model (solver='liblinear') from the Python sklearn library, based on the average methylation rate of nine markers in the training set. In the `class_weight` parameter, 0 represents negative samples and 1 represents positive samples, with the weight of positive samples being a multiple of that of negative samples.
[0113] Table 11 Model Parameters for Liver Cancer Methylation Items
[0114] Model predicted value = Σ (average methylation rate_i × weight coefficient_i). If the predicted value > threshold, it is considered positive.
[0115] Table 12 Training set model for liver cancer methylation items
[0116] Combination Figure 1 , Figure 2 and Figure 3The training set shown shows that among the three training models, Model 1 identified 98 positive and 52 negative cases, with a sensitivity of 93.33% and a specificity of 96.3%, a threshold of 0.93, and an area under the ROC curve (AUC) of 0.982892, demonstrating the best identification ability. Model 2 identified 94 positive and 54 negative cases, with a sensitivity of 89.52% and a specificity of 100%, a threshold of 0.68, and an AUC of 0.982187. Model 3 identified 99 positive and 50 negative cases, with a sensitivity of 94.29% and a specificity of 92.59%, a threshold of 0.28, and an AUC of 0.982011. Training results: Model 1 is the best, with a sensitivity of 93.33% (98 / 105), a specificity of 96.3% (52 / 54), a threshold of 0.93, and an AUC of 0.982892.
[0117] Table 13 Validation set results for hepatocellular carcinoma methylation projects
[0118] Combination Figure 4 , Figure 5 and Figure 6 In the validation set (43 cases of liver cancer + 37 healthy individuals), Model 1 showed 41 positive cases (sensitivity 95.35%), 36 negative cases (specificity 97.3%), and an area under the ROC curve (AUC) of 0.996229. Model 2 showed 40 positive cases (sensitivity 93.02%), 37 negative cases (specificity 100%), and an area under the ROC curve (AUC) of 0.996229. Model 3 showed 41 positive cases (sensitivity 95.35%), 37 negative cases (specificity 100%), and an area under the ROC curve (AUC) of 0.996229.
[0119] Example 4 This embodiment provides a computer-readable storage medium storing a set of executable program instructions. The set of executable program instructions is loaded by a processor and executed to construct the above-described method for early liver cancer diagnosis, and to diagnose early liver cancer.
[0120] In addition, an early liver cancer diagnosis device is provided, which includes: an input module, a control module and an output module; The input module is configured to: obtain the methylation rate of the region where each marker in the combination of methylation markers is located in the subject's biological sample, wherein the combination of methylation markers is the combination of methylation markers mentioned above; The control module includes: a results analysis module, which is configured to generate early liver cancer risk prediction results for the subject based on the methylation rate of the combination of methylation markers contained in the subject's sample; The output module is configured to output the early liver cancer risk prediction results for the subjects.
[0121] The results analysis module is configured to: calculate the model prediction value of the early liver cancer diagnosis model based on the average methylation rate of all methylation sites in the region of each marker in the methylation marker combination shown in Table 1 of the subject samples, according to the following formula: Model predicted value = Σ (average methylation rate_i × weight coefficient_i), where i represents the marker number, and its value ranges from 1 to 9; the model predicted value is compared with the threshold. If the model predicted value is greater than the threshold, it is judged as early-stage liver cancer positive.
[0122] The aforementioned device can be integrated into a cloud platform, supporting batch processing. Clinical application: In screening high-risk populations, positive samples can be further confirmed endoscopically, reducing unnecessary invasive examinations.
[0123] The above embodiments verify the effectiveness of the methylation biomarker combination, product, and device of the present invention in the early detection of liver cancer, which can achieve non-invasive, high-sensitivity, high-specificity, and high-accuracy detection.
[0124] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. The application of a reagent for detecting a combination of methylation markers in the preparation of auxiliary diagnostic or diagnostic products for early liver cancer, characterized in that, The reagent for detecting the methylation biomarker combination is used to detect the methylation level of the methylation biomarker combination, which includes biomarkers 1-9. The positional information of biomarkers 1-9 based on the GRch37 reference genome is as follows: Marker 1: chr12:131303649-131303805; Marker 2: chr5:37834882-37835039; Marker 3: chr5:42994735-42994854; Marker 4: chr2:264102-264234; Marker 5: chr17:29298077-29298218; Marker 6: chr3:179168821-179168951; Marker 7: chr6:26240698-26240819; Marker 8: chr1:226411760-226411845; Marker 9: chr7:27214013-27214164.
2. The application according to claim 1, characterized in that, The early liver cancer auxiliary diagnostic or diagnostic products are selected from reagent kits, gene chips, and detectors.
3. The application according to claim 2, characterized in that, The reagent used to detect the combination of methylation markers is selected from at least one of the reagents used in methods for detecting the methylation level of the combination of methylation markers: Methylation chip method, qPCR method, digital PCR method, second-generation sequencing method, third-generation sequencing method, HPLC method and MassArray.
4. The application according to claim 2, characterized in that, The reagents used to detect the combination of methylation markers are those used in bisulfite conversion sequencing or pyrosequencing.
5. The application according to claim 2, characterized in that, The reagent for detecting the combination of methylation markers is a primer combination for detecting the combination of methylation markers. The primer combination includes: a first primer pair, a second primer pair, a third primer pair, a fourth primer pair, a fifth primer pair, a sixth primer pair, a seventh primer pair, an eighth primer pair, and a ninth primer pair, respectively, for detecting markers 1 to 9. The nucleotide sequences of the first primer pair to the ninth primer pair are shown in SEQ ID NO.1-SEQ ID NO.18, respectively.
6. A primer combination for the auxiliary diagnosis or diagnosis of early-stage liver cancer, characterized in that, It includes: a first primer pair, a second primer pair, a third primer pair, a fourth primer pair, a fifth primer pair, a sixth primer pair, a seventh primer pair, an eighth primer pair, and a ninth primer pair, respectively, for detecting markers 1 to 9 as described in any one of claims 1-5, wherein the nucleotide sequences of the first primer pair to the ninth primer pair are as shown in SEQ ID NO.1-SEQ ID NO.18, respectively.
7. A reagent kit, gene chip, or detection device, characterized in that, It includes the primer combination for the auxiliary diagnosis or diagnosis of early liver cancer as described in claim 6.
8. The reagent kit, gene chip, or detection device according to claim 7, characterized in that, The kit, gene chip, or detection device also includes detection primers for detecting the methylation level of the internal reference gene; Its primer sequences are shown in SEQ ID NO.19-SEQ ID NO.
20.
9. A method for constructing an auxiliary diagnostic model or diagnostic model for early-stage liver cancer, characterized in that, The early liver cancer auxiliary diagnosis or diagnostic model is constructed by the following method: obtaining the methylation rate of each marker in the combination of methylation markers in any one of claims 1-5 in the training samples to establish a dataset; and using the dataset to construct the early liver cancer auxiliary diagnosis or diagnostic model through a machine learning model. The machine learning model is selected from at least one of the following: logistic regression, random forest, K-nearest neighbors, support vector machine, gradient boosting machine, AdaBoost, XGBoost, Naive Bayes, and DT decision tree; When the machine learning model is logistic regression, the model prediction value of the early liver cancer auxiliary diagnosis or diagnostic model is calculated based on the average methylation rate of all methylation sites in the region where each marker in the combination of methylation markers in the measured sample is located. Model predicted value = Σ (average methylation rate_i × weight coefficient_i), where i represents the marker number, and its value ranges from 1 to 9; the model predicted value is compared with a preset threshold. If the model predicted value is greater than the preset threshold, it is judged as early-stage liver cancer positive. The sample to be tested is selected from cells, tissues, plasma, urine or whole blood.
10. A computer-readable storage medium storing an executable program instruction set, the executable program instruction set being loaded by a processor and executed by the method for constructing the early liver cancer diagnostic model according to claim 9, and for diagnosing early liver cancer.
Citation Information
Patent Citations
Electrical discharge tube with two or more liquid electrodes.
CH264120A
process for thinning conductive material wires.
CH264123A
stroller.
CH264159A
device for tightening and screwing spokes for bicycles and motorcycles.
CH264166A
installation comprising airways for the transport of loads.
CH264178A
